Anthony T. Buatti Pharmacy Resident
Research Symposium - May 9, 2023

DATE: May 9, 2023

LOCATION:
Feinstein Institutes for Medical Research - Northwell Health
350 Community Drive
Manhasset, NY 11030

TIME:
6:00 PM - 6:30 PM Registration
6:30 PM - 9:00 PM Educational Program and Dinner

EDUCATIONAL PROGRAM TOPIC: 

Resident Research Topics

(See Below for Speakers, Topics & Learning Objectives)

INTENDED AUDIENCE:
Health-system pharmacists, technicians and pharmacy students. This is a knowledge-based program. Cost: There is no charge for members of the LISHP. 

Non-Member charge at door is $50.00, no refund

PHARMACIST ACCREDITATION STATEMENT: 
NYSCHP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2.0 contact hour(s) (0.2 CEUs) of ACPE approved continuing education. In order to receive credit, the participant must provide the CE code given at the event on the survey which will be emailed out after the meeting.  Participants must provide this code within 45 days of the event.  It will take up to 60 days to be uploaded to MY CPE Monitor.

LISHP may use picture for promotional purposes.

RSVP by May 1, 2023, electronic responses automatically generate a reply; manual responses e-mail Amanda Waldeck at lishpharmacists@gmail.com.

Register Now! 

 

Daniya Mathew, PharmD 

North Shore University Hospital, PGY1 Resident

Association between tixagevimab/cilgavimab (Evusheld™) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality 

Objectives:

-Discuss the place in therapy for tixagevimab/cilgavimab (Evusheld™) in pre-exposure prophylaxis for SARS-CoV-2 

-Expand upon literature for tixagevimab/cilgavimab’s safety and efficacy in SARS-CoV-2 infection, and discuss research in progress  

 

Lauren Eng, PharmD 

Stony Brook University Hospital, PGY1 Resident

Microbial Trends in Neutropenic and Non-Neutropenic Oncology Patients Admitted to a Tertiary Care Hospital

Objectives:

-Discover the common pathogens cultured in neutropenic and non-neutropenic oncology patients admitted to a tertiary care hospital

-Recognize the distribution of antimicrobial resistance among pathogens isolated in neutropenic and non-neutropenic oncology patients

 

Toobah Wali, PharmD 

Long Island Jewish Medical Center, PGY2 Infectious Diseases Resident

The Role of mecA Detection in Antimicrobial Stewardship: Can Rapid Diagnostics Improve Time to Antibiotic De-Escalation in Patients with S. Lugdunensis Bacteremia?

Objectives:

-Assess the impact of rapid detection of mecA-negative Staphylococcus lugdunensis bacteremia on antibiotic de-escalation

-Evaluate the clinical outcomes of vancomycin IV and beta-lactam IV antibiotic treatment prescribing patterns 

 

Edwin Gruda, PharmD

St. Francis Hospital & Heart Center, PGY1 Resident

Retrospective Medication Use Evaluation of Intravenous Immunoglobulin in the Inpatient and Outpatient Setting of a Community Hospital.

Objectives:

-Incorporate a standardized pre-medication order set for patients receiving IVIG

-Analyze the potential cost saving associated with transitioning the dosing of IVIG based upon Ideal Body Weight instead of Actual Body Weight

 

Melody Song, PharmD

NYU Langone Hospital Long Island, PGY1 Resident

Safety Evaluation of Serotonin (5-HT3) Antagonists

Objectives:

-Evaluate the current primary literatures on the comparative safety of serotonin antagonists

-Review the indication and effectiveness of serotonin antagonists in prevention and treatment of nausea & vomiting

-Analyze the data on the change in QTc interval with use of serotonin antagonists

 

Ngan Nguyen, PharmD, AAHIVP

Northwell Health, PGY2 Ambulatory Care Resident

Implementation of A Pharmacist Led Long-Acting Injectable Cabotegravir/Rilpivirine Program for Human Immunodeficiency Virus-1 At Health System-Based Clinics in The New York Metropolitan Area

Objectives:

-Describe the evaluation process and considerations of a pharmacist led CAB/RPV-LA initiation program

-Expand upon the literature of clinical experiences with transitioning patients to CAB/RPV-LA

-Identify strengths and limitations within the pharmacist-led initiative that may be informative for other practice sites